Role of the Kallikrein-kinin System in Septic Cardiomyopathy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

640 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-10-01

Study Completion Date

2025-10-14

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to investigate whether there are differential expressions of molecules in the kallikrein-kinin system (KKS) pathway in septic cardiomyopathy, and to analyze their regulatory mechanisms and gene expression changes.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Multicenter Cross-sectional Study of Cardiac Ultrasound Phenotypes in Patients With Sepsis

NCT05161104

Cardiac Ultrasound Phenotypes Septic Myocardial Suppression Hyperdynamic State Left Ventricular Function in Sepsis Patients +1 more

ENROLLING_BY_INVITATION

Study on the Construction and Application of Early Warning Model of Sepsis in Critically Ill Patients

NCT06904001

Sepsis Sepsis and Septic Shock Infection

ENROLLING_BY_INVITATION

The Study of NT-proBNP Combined With HS-cTnT in Evaluating the Prognosis of Sepsis

NCT04963699

Sepsis

COMPLETED

Potential Diagnostic and Prognostic Value of microRNAs for the Patients of Sepsis-induced Myocardial Injury

NCT02835573

Sepsis-induced Myocardial Injury

UNKNOWN

Study on the Establishment of a System for Early Warning and Prognostic Evaluation of Patients With Sepsis

NCT05229328

Sepsis Prognosis Liver Injury +2 more

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study is designed as a prospective, single-center, prospective case-control study. The research plan mainly aims to collect clinical data and blood samples from patients with septic cardiomyopathy and the control group within the next 3 years (October 2023 to October 2025). Diagnostic criteria are as follows: (1) Diagnosis of sepsis is based on the SEPSIS 3.0 criteria, which is defined as a rapid increase in SOFA score by ≥2 points after infection as a clinical criterion for sepsis-related organ dysfunction. (2) Diagnostic criteria for septic cardiomyopathy include: diagnosis of sepsis and elevation of cardiac markers \[cardiac troponin I (cTnI) or BNP\]; systolic dysfunction: echocardiography shows LVEF \< 50%; diastolic dysfunction: Doppler ultrasound shows an E/A ratio (rapid filling phase/atrial contraction phase) ≤1 at the mitral valve; BNP \> 200 pg/mL; left ventricular fractional shortening (FS) \> 25%; normal or increased wall thickness, decreased left ventricular filling rate.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sepsis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Sepsis

No intervention

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

(1) Age range greater than 18 years. (2) Patients diagnosed with septic cardiomyopathy. (3) Clear determination of the cause of myocardial injury, such as the source of infection, bacterial culture results, etc. (4) Patients who are capable of cooperating and completing the necessary examinations and treatments.

\-

Exclusion Criteria

(1) Presence of other significant underlying cardiovascular diseases, such as coronary heart disease, heart failure, etc. (2) Presence of other organ dysfunction that poses a significant threat to life, such as respiratory failure, liver failure, etc. (3) Presence of severe infections or inflammatory diseases unrelated to myocardial injury, such as severe acute pancreatitis. (4) History of receiving interventional treatments, such as immunomodulatory agents, anti-inflammatory drugs, etc. (5) Pregnant or lactating women. (6) Pediatric patients who are under the age of majority.

\-

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No